Jones David Scott 4

4 · EyePoint Pharmaceuticals, Inc. · Filed Jan 29, 2024

Form 4

Period: 2024-01-26

SVP & Chief Commercial Officer

Transactions

Exercise/Conversion
Stock Option (Right to Buy)
2024-01-26−16,413→ 68,742 total
Exercise: $3.26Exp: 2033-01-05→ Common Stock (16,413 underlying)
Sale
Common Stock
2024-01-26$25.45/sh−16,413$417,653→ 47,566 total
Sale
Common Stock
2024-01-26$25.27/sh−9,604$242,717→ 37,962 total
Exercise/Conversion
Common Stock
2024-01-26$12.90/sh+9,604$123,892→ 47,566 total
Exercise/Conversion
Common Stock
2024-01-26$3.26/sh+16,413$53,506→ 63,979 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-01-26−9,604→ 8,721 total
Exercise: $12.90Exp: 2030-02-28→ Common Stock (9,604 underlying)

Footnotes (4)

[F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $26.00. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
[F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.88. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
[F3]The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020
[F4]The option to purchase will vest and become exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.

Documents

1 file